Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
5.08
-0.20 (-3.79%)
At close: Sep 12, 2025, 4:00 PM EDT
5.04
-0.04 (-0.79%)
After-hours: Sep 12, 2025, 7:30 PM EDT

Cellectar Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Net Income
-29.07-44.58-42.77-31.79-24.12-15.09
Upgrade
Depreciation & Amortization
0.250.290.190.150.150.14
Upgrade
Loss (Gain) From Sale of Assets
0.150.15-00-
Upgrade
Stock-Based Compensation
4.154.272.411.451.120.47
Upgrade
Other Operating Activities
-8.65-5.994.323.280.08-0.12
Upgrade
Change in Accounts Payable
-1.78-1.593.71.620.410.78
Upgrade
Change in Other Net Operating Assets
0.38-0.13-0.220.06-0.21-0.11
Upgrade
Operating Cash Flow
-34.58-47.58-32.38-25.22-22.57-13.93
Upgrade
Capital Expenditures
-0.06-0.1-0.86-0.23-0.14-0.06
Upgrade
Investing Cash Flow
-0.06-0.1-0.86-0.23-0.14-0.06
Upgrade
Long-Term Debt Issued
-----0.18
Upgrade
Total Debt Issued
-----0.18
Upgrade
Net Debt Issued (Repaid)
-----0.18
Upgrade
Issuance of Common Stock
19.8161.4122.949.611.2560.36
Upgrade
Financing Cash Flow
19.8161.4122.949.611.2560.55
Upgrade
Net Cash Flow
-14.8313.72-10.3-15.84-21.4646.55
Upgrade
Free Cash Flow
-34.64-47.69-33.24-25.45-22.71-14
Upgrade
Free Cash Flow Per Share
-23.66-38.52-81.60-108.20-122.72-211.91
Upgrade
Cash Interest Paid
-----0
Upgrade
Levered Free Cash Flow
-28.59-43.97-8.99-8.83-13.63-8.23
Upgrade
Unlevered Free Cash Flow
-28.59-43.97-8.99-8.83-13.63-8.23
Upgrade
Change in Working Capital
-1.4-1.733.481.680.20.67
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q